French tech Keen Eye to bring its AI to Iris Pharma in partnership deal

blue eye
Keen Eye will bring its artificial intelligence applications to CRO Iris Pharma as part of a new collaboration. (Pixabay)

French tech company Keen Eye will bring its artificial intelligence applications to Iris Pharma, a CRO focused on ophthalmology, as part of a new collaboration.

Under the agreement, Keen Eye’s AI is expected to make assays much faster and more reliable and efficient. Iris Pharma offers preclinical and clinical services for drug and medical device development.

Financial terms of the deal weren’t disclosed.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

“The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development,” Yann Quentric, Iris Pharma’s president, said in a statement.

“We are expecting to contribute to the most challenging image-based assays to better fight eye diseases,” Keen Eye’s founder and chief executive, Sylvain Berlemont, added.

Iris, which is also headquartered in France, is a full-service research organization with a long history of helping to get ocular drugs and devices onto the market.